News

Looking at pulmonary fibrosis (PF) as an age-related disease and working with a gene therapy that lengthens the life of lung cells, researchers report that they were able to lessen — and even stop — lung fibrosis in mice. “This is the first time that pulmonary fibrosis has been treated as an age-related disease, looking for rejuvenating the affected tissues,” Maria A. Blasco, study's lead author and group leader at the Spanish National Cancer Research Centre (CNIO), in Madrid, said in a press release. The study “Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres” was published in the journal eLife.

A pivotal Phase 3 trial evaluating PBI-4050, a potential treatment of idiopathic pulmonary fibrosis, will be open to all patients with mild-to-moderate IPF regardless of whether they are also taking Ofev (nintedanib) or not, the therapy’s developer, Prometic Life Sciences, announced. The trial, in other words, will evaluate the efficacy and safety of…

A natural compound called gentiopicroside effectively lowers inflammation and tissue scarring in a mouse model of pulmonary fibrosis (PF), say researchers at China’s Kunming Medical University. Since the plant-derived compound targets both fibrotic and inflammatory processes, researchers suggested it may be an ideal drug candidate for lung fibrosis — particularly…

This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…

Members of an unusual singing group in Bristol, England, are not just having fun, but learning more about their lung diseases. In addition to helping them explore breathing and breathlessness, it’s helping researchers learn about the disorders as well. The group, which includes pulmonary fibrosis patients, is part of a…

Advanced Interactive Response Systems (AIRS), Owlstone Medical and patientMpower are the three winners of the $1 million IPF Catalyst Challenge presented by Three Lakes Partners, a philanthropy organization financing research of idiopathic pulmonary fibrosis (IPF). The three winners will receive $333,333 each to develop their projects. Level Ex received the competition’s Audience…

A project that aims to develop a new system to deliver therapies specifically to the lungs of patients with pulmonary fibrosis (PF) was awarded a research grant by the University of Pittsburgh’s Center for Medical Innovation. The funding was part of the center’s 2017 Round 2 Pilot Funding Program…

The IPF Catalyst Challenge is being held in Chicago, Illinois today as nine finalists make their final pitch in a competition for $1 million in funding for innovative, meaningful solutions to improve the quality of life for people living with idiopathic pulmonary fibrosis (IPF). Among the finalists is patientMpower, a…

Only a minority of patients with interstitial lung disease (ILD) swiftly receive a correct diagnosis, while more than half are misdiagnosed at least once, finds a Pulmonary Fibrosis Foundation (PFF) survey of 600 ILD patients. Meanwhile, patients go through invasive and costly diagnostic procedures — often without the desired result.

The Pulmonary Fibrosis Foundation plans to expand its U.S. Care Center Network from the existing 45 facilities, which provide diagnosis and treatment. The network started with nine sites when it was launched in 2013. The foundation wants to see enough centers so 90 percent of patients in urban areas…